

U.S. Securities and Exchange Commission
Washington, D.C. 20549

Form 10-Q

(Mark One)

QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended June 30, 2013

TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT

For the transition period from _____ to _____

Commission file number: **000-30415**

Health Enhancement Products, Inc.

(Exact name of small business issuer as specified in its charter)

Nevada
(State or other jurisdiction of
incorporation or organization)

87-0699977
(IRS Employer Identification No.)

7 West Square Lake Rd., Bloomfield Hills, MI 48302

(Address of principal executive offices)

(248) 452 9866
(Issuer's telephone number)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Indicate by checkmark whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of regulation ST (Sec. 232.405) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).

Yes No

Indicate by checkmark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See the definitions of "large accelerated filer," "accelerated filer" and "smaller reporting company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Indicate by check mark whether the issuer is a shell company (as defined in Rule 12-b2 of the Exchange Act).

Yes No

APPLICABLE ONLY TO CORPORATE ISSUERS

There were 109,289,384 shares of common stock, \$0.001 par value, outstanding at August 6, 2013.

FORM 10-Q
HEALTH ENHANCEMENT PRODUCTS, INC.
INDEX

| | |
|---|----|
| PART I – FINANCIAL INFORMATION | 3 |
| Item 1. Consolidated Financial Statements | 3 |
| Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations | 19 |
| Item 4T. Controls and Procedures | 22 |
| | |
| PART II – OTHER INFORMATION | 22 |
| Item 2. Unregistered Sales of Equity Securities and Use of Proceeds | 22 |
| Item 5. Other information | 23 |
| Item 6. Exhibits | 23 |

(Inapplicable items have been omitted)

PART I – FINANCIAL INFORMATION**ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS****HEALTH ENHANCEMENT PRODUCTS, INC. AND SUBSIDIARIES
CONDENSED CONSOLIDATED BALANCE SHEET**

| | June 30, 2013 (Unaudited) | December 31, 2012 |
|---|------------------------------|--------------------|
| ASSETS | | |
| CURRENT ASSETS: | | |
| Cash | \$ 254,604 | \$ 47,147 |
| Prepaid Expenses | 87,328 | 8,701 |
| Miscellaneous Receivable | 118,467 | - |
| Deferred Finance Costs | 34,957 | 34,957 |
| Total Current Assets | <u>495,356</u> | <u>90,805</u> |
| PROPERTY AND EQUIPMENT, NET | <u>-</u> | <u>13,203</u> |
| OTHER ASSETS: | | |
| Definite-life intangible Assets, net | - | 6,234 |
| Deposits | 845 | 123,762 |
| Total Other Assets | <u>845</u> | <u>129,996</u> |
| | <u>\$ 496,201</u> | <u>\$ 234,004</u> |
| LIABILITIES AND STOCKHOLDERS' DEFICIT | | |
| CURRENT LIABILITIES: | | |
| Accounts Payable | \$ 802,501 | \$ 938,640 |
| Customer deposits | - | 27,837 |
| Loan Payable – Other | 289,592 | 243,592 |
| Loan Payable – Related Party | - | 15,362 |
| Obligation to issue common stock and warrants | 273 | 337,478 |
| Convertible Debenture Payable, less discount of \$421,611 and \$517,542 at June 30, 2013 and December 31, 2012 | 1,260,989 | 482,458 |
| Derivative Liability | 5,692,826 | 1,026,128 |
| Deferred Rent | - | 19,110 |
| Accrued Liabilities | 661,129 | 270,682 |
| Total Current Liabilities | <u>8,707,310</u> | <u>3,361,287</u> |
| LONG TERM LIABILITIES: | | |
| Convertible Debenture Payable, less discount of \$ 1,235,616 and \$223,692 at June 30, 2013 and December 31, 2012 | 399,384 | 593,908 |
| Deferred revenue, noncurrent | - | 235,000 |
| Total Long term Liabilities | <u>399,384</u> | <u>828,908</u> |
| TOTAL LIABILITIES | <u>9,106,694</u> | <u>4,190,195</u> |
| COMMITMENTS AND CONTINGENCIES | | |
| STOCKHOLDERS' DEFICIT: | | |
| Common stock, \$.001 par value, 200,000,000 shares authorized 107,812,111 and 105,317,816 issued and outstanding at at June 30, 2013 and December 31, 2012 | 107,812 | 105,318 |
| Additional Paid-In Capital | 29,468,346 | 28,448,705 |
| Accumulated deficit | (38,186,651) | (32,510,214) |
| Total Stockholders' Deficit | <u>(8,610,493)</u> | <u>(3,956,191)</u> |
| | <u>\$ 496,201</u> | <u>\$ 234,004</u> |

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

HEALTH ENHANCEMENT PRODUCTS, INC. AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

| | For the three Months ended June 30, 2013 | For the three Months ended June 30, 2012 | For the six Months ended June 30, 2013 | For the six Months ended June 30, 2012 |
|---|--|--|--|--|
| REVENUES: | \$ - | \$ - | \$ - | \$ - |
| COSTS AND EXPENSES: | | | | |
| General and Administrative | 472,003 | 162,453 | 736,416 | 315,938 |
| Professional fees and Consulting expense | 99,480 | 136,914 | 240,956 | 367,597 |
| Research and Development | <u>310,917</u> | <u>182,417</u> | <u>440,365</u> | <u>305,468</u> |
| Total Costs and Expenses | <u>882,400</u> | <u>481,785</u> | <u>1,417,737</u> | <u>989,003</u> |
| LOSS FROM OPERATIONS | (882,400) | (481,785) | (1,417,737) | (989,003) |
| OTHER INCOME (EXPENSE): | | | | |
| Other Income | 262,837 | - | 262,837 | - |
| Fair Value Adjustment of Derivative Liability | (1,243,627) | 492,870 | (1,382,376) | 379,315 |
| Amortization of Debt Discount | (286,536) | (175,713) | (461,095) | (286,341) |
| Amortization of Deferred Finance Costs | - | (4,286) | - | (8,570) |
| Finance Costs | (2,543,758) | (543,816) | (2,571,910) | (842,198) |
| Interest expense | <u>(55,848)</u> | <u>(35,823)</u> | <u>(106,155)</u> | <u>(60,475)</u> |
| Total Other Income (Expense) | <u>(3,866,932)</u> | <u>(266,768)</u> | <u>(4,258,699)</u> | <u>(818,269)</u> |
| NET LOSS | <u>\$ (4,749,332)</u> | <u>\$ (748,552)</u> | <u>\$ (5,676,436)</u> | <u>\$ (1,807,272)</u> |
| BASIC AND DILUTED LOSS PER SHARE | <u>\$ (0.04)</u> | <u>\$ (0.01)</u> | <u>\$ (0.05)</u> | <u>\$ (0.02)</u> |
| WEIGHTED AVERAGE BASIC AND DILUTED SHARES OUTSTANDING | <u>106,828,157</u> | <u>100,203,054</u> | <u>106,086,608</u> | <u>100,119,537</u> |

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

HEALTH ENHANCEMENT PRODUCTS, INC. AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

| | For the Six Months Ended June 30, 2013 (Unaudited) | For the Six Months Ended June 30, 2012 (Unaudited) |
|--|---|---|
| Cash Flows for Operating Activities: | | |
| Net (Loss) | \$ (5,676,436) | \$ (1,807,272) |
| Adjustments to reconcile net loss to net cash used by operating activities: | | |
| Stock and warrants issued for services rendered | 250,640 | - |
| Warrants issued for Directors' Fees | 13,385 | 21,441 |
| Finance costs paid in stock and warrants | 612,969 | 819,249 |
| Amortization of deferred finance costs | - | 8,570 |
| Deferred finance costs | 1,907,234 | - |
| Amortization of bond discount | 461,095 | 286,341 |
| Amortization of intangibles | 6,234 | 484 |
| Depreciation expense | 13,203 | 34,566 |
| Fair value adjustment of Derivative Liability | 1,382,376 | (379,315) |
| (Decrease) in deferred rent | (19,110) | (63,653) |
| Changes in assets and liabilities: | | |
| (Increase) in prepaid expenses | (78,627) | (27,277) |
| (Increase) in miscellaneous receivable | (118,468) | - |
| Decrease (Increase) in security deposits | 122,917 | (845) |
| Increase (Decrease) in accounts payable | (136,139) | 62,338 |
| (Decrease) in deferred revenue | (235,000) | - |
| (Decrease) in customer deposits | (27,837) | - |
| Increase in accrued liabilities | 113,383 | 97,373 |
| | (1,408,181) | (948,002) |
| Net Cash (Used) by Operating Activities | | |
| Cash Flows from Investing Activities: | | |
| Capital expenditures | - | (3,500) |
| Net Cash (Used) by Investing Activities | - | (3,500) |
| Cash Flow from Financing Activities: | | |
| Repayment of Loan Payable, related party | (362) | - |
| Proceeds of loan payable, other | 31,000 | 57,000 |
| Payment of Deferred Finance Costs | - | (34,958) |
| Payments of other borrowings | - | (7,683) |
| Proceeds from issuance of convertible debentures | 1,500,000 | 757,000 |
| Proceeds from sale of common stock and exercise of warrants | 85,000 | 50,000 |
| Net Cash Provided by Financing Activities | 1,615,638 | 821,359 |
| Increase (Decrease) in Cash | 207,457 | (130,143) |
| Cash at Beginning of Period | 47,147 | 225,696 |
| Cash at End of Period | \$ 254,604 | \$ 95,553 |
| Supplemental Disclosures of Cash Flow Information: | | |
| Cash paid during the period for: | | |
| Interest | \$ - | \$ - |
| Income Taxes | \$ - | \$ - |

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

HEALTH ENHANCEMENT PRODUCTS, INC. AND SUBSIDIARIES
UNAUDITED CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS *[Continued]*

Supplemental Disclosure of Non-Cash Investing and Financing Activities:

Six Months Ended June 30, 2013:

During the quarter ended March 31, 2013, the Company issued 21,111 shares of its common stock in return for a cashless exercise of 35,000 common stock warrants.

During the quarter ended March 31, 2013, the Company issued convertible debentures totaling \$500,000 and recorded \$377,088 in discounts on debentures.

During the quarter ended March 31, 2013, \$15,000 in Loans Payable – Related Party was transferred to Loans Payable – Other (HEP Investments, LLC) pursuant to a Participation Agreement entered into by the two parties on March 18, 2013 (See Note 6 – Convertible Debt).

During the quarter ended June 30, 2013, the Company issued 682,000 shares of its common stock in return for cashless exercises of 1,400,000 common stock warrants.

During the quarter ended June 30, 2013, the Company issued convertible debentures totaling \$1,000,000 and recorded \$1,000,000 in discounts on debentures.

During the quarter ended June 30, 2013, the Company reclassified \$277,064 of Obligation to Issue Common Stock to Accrued Liabilities.

During the quarter ended June 30, 2013, the Company reclassified issued 600,000 shares of its common stock valued at \$72,000 as consideration for payment of Obligations to Issue Common Stock.

Six Months Ended June 30, 2012:

During the quarter ended March 31, 2012, the Company issued convertible debentures totaling \$432,000 and recorded \$332,000 in discounts on debentures.

During the quarter ended June 30, 2012, the Company issued convertible debentures totaling \$325,000 and recorded \$500,000 in discounts on debentures.

During the quarter ended June 30, 2012, several three year 1% convertible notes in the aggregate principal amount of \$155,100, with various maturity dates during 2011 were extended for an additional two years. The Company incurred no additional cost as a result of these extensions.

The accompanying notes are an integral part of these unaudited condensed consolidated financial statements

HEALTH ENHANCEMENT PRODUCTS, INC. AND SUBSIDIARIES
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

NOTE 1 – BASIS OF PRESENTATION

The accompanying unaudited condensed consolidated financial statements include the accounts of Health Enhancement Products, Inc. and its wholly-owned subsidiaries (collectively, the “Company”). All significant inter-company accounts and transactions have been eliminated in consolidation. In the opinion of the Company’s management, the financial statements contain all adjustments (consisting of only normal recurring adjustments) necessary to present fairly the information set forth therein. These consolidated financial statements are condensed, and therefore do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. These unaudited condensed consolidated financial statements should be read in conjunction with the Company’s December 31, 2012 consolidated audited financial statements and supplementary data included in the Annual Report on Form 10-K filed with the SEC on March 25, 2013.

The results of operations for the six months ended June 30, 2013 are not necessarily indicative of the results to be expected for the fiscal year ending December 31, 2013, or any other period.

The Company incurred net losses of \$5,676,436 and \$1,807,272 for the six months ended June 30, 2013 and 2012, respectively. In addition, the Company had a working capital deficiency of \$8,211,954 and a stockholders’ deficit of \$8,610,493 at June 30, 2013. These factors continue to raise substantial doubt about the Company’s ability to continue as a going concern. During the first six months of 2013, the Company raised \$85,000 from the issuance of 682,000 shares of its common stock, \$1,500,000 in net proceeds from the issuance of convertible debentures and \$31,000 from loans payable - other. There can be no assurance that the Company will be able to raise additional capital.

The accompanying condensed consolidated financial statements do not include any adjustments related to the recoverability or classification of asset-carrying amounts or the amounts and classifications of liabilities that may result should the Company be unable to continue as a going concern.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Accounting Estimates

The Company’s consolidated financial statements have been prepared in conformity with generally accepted accounting principles in the United States of America, which require management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amount of revenues and expenses during the reporting period. Actual results could differ from those estimates. Management uses its best judgment in valuing these estimates and may, as warranted, solicit external professional advice and other assumptions believed to be reasonable.

Cash and Cash Equivalents

For the purpose of the statements of cash flows, cash equivalents include time deposits, certificates of deposit and all highly liquid debt instruments with original maturities of three months or less. The Company maintains cash and cash equivalents balances at financial institutions and are insured by the Federal Deposit Insurance Corporation up to \$250,000. At times, balances in certain bank accounts may exceed the FDIC insured limits. Cash equivalents consist of highly liquid investments with an original maturity of three months or less when purchased. At June 30, 2013, the Company did not have any cash equivalents.

Property and Equipment

Property and equipment consists of furniture and office equipment, and are carried at cost less allowances for depreciation and amortization. Depreciation is determined by using the straight-line method over the estimated useful lives of the related assets, generally three to five years. Repair and maintenance costs that do not improve service potential or extend the economic life of an existing fixed asset are expended as incurred.

Fair Value Measurements

The authoritative guidance for fair value measurements defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or the most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. Market participants are buyers and sellers in the principal market that are (i) independent, (ii) knowledgeable, (iii) able to transact, and (iv) willing to transact. The guidance describes a fair value hierarchy based on the levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value which are the following:

Level 1 – Quoted prices in active markets for identical assets or liabilities.

Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or corroborated by observable market data or substantially the full term of the assets or liabilities.

Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the value of the assets or liabilities.

The Company's financial instruments include cash and cash equivalents, accounts payable, loans payable, obligations to issue common stock, accrued expenses and customer deposits. All of these items were determined to be Level 1 fair value measurements.

The carrying amounts of cash and equivalents, accounts payable, loans payable, obligation to issue common stock, and short-term convertible debentures all approximate fair value because of the short maturity of these instruments. The recorded value of long-term debt approximates its fair value as the terms and rates approximate market rates.

Deferred Financing Costs

The Company follows authoritative guidance for accounting for financing costs as it relates to convertible debt issuance cost. These costs are deferred and amortized over the term of the debt period or until redemption of the convertible debentures. Amortization of deferred financing costs amounted to \$ -0- and \$8,570 for the six months ended June 30, 2013 and 2012, respectively.

Impairment of Long-Lived Assets

We review our long-lived assets for impairment whenever events and circumstances indicate that the carrying value of an asset might not be recoverable. An impairment loss, measured as the amount by which the carrying value exceeds the fair value, is recognized if the carrying amount exceeds estimated undiscounted future cash flows.

The Company believes its current assumptions and estimates are reasonable and appropriate; however, unanticipated events and changes in market conditions could affect such estimates, resulting in the need for an impairment charge in future periods. During the period ended June 30, 2013, the Company decided that the remainder of the cost of the patents related to its former product ProAlgaZyme should be written off in the amount of \$6,234. The decision was based on the lack of revenue generated by this product over the course of the prior year or for the foreseeable future.

Revenue Recognition

For revenue from product sales, the Company recognizes revenue in accordance with Staff Accounting Bulletin No. 104, "Revenue Recognition" ("SAB No. 104"), which superseded Staff Accounting Bulletin No. 101, "Revenue Recognition in Financial Statements" ("SAB No. 101"). SAB No. 104 requires that four basic criteria must be met before revenue can be recognized: (1) persuasive evidence of an arrangement exists; (2) delivery has occurred; (3) the selling price is fixed and determinable; and (4) collectability is reasonably assured. Determination of criteria (3) and (4) are based on management's judgment regarding the fixed nature of the selling prices of the products delivered and the collectability of those amounts. Provisions for discounts and rebates to customers, estimated returns and allowances, and other adjustments are provided for in the same period the related sales are recorded. The Company ceased the sales of its sole product in the fourth quarter of 2011, and therefore recognized no provision for the six months ended June 30, 2013 or June 30, 2012.

Shipping and Handling Costs

Shipping and handling costs are expensed as incurred. For the six months ended June 30, 2013 and 2012, no shipping and handling costs were incurred.

Research and Development

Research and development costs are expensed as incurred. The Company accounts for research and development expenses under two main categories:

- Research Expenses, consisting of salaries and equipment and related expenses incurred for product research studies conducted primarily within the Company and by Company personnel. Research expenses were approximately \$66,734 and \$71,493 for the six months ended June 30, 2013 and 2012, respectively;
- Clinical Studies Expenses, consisting of fees, charges, and related expenses incurred in the conduct of clinical studies conducted with Company products by independent external entities. External clinical studies expenses were approximately \$373,631 and \$233,975 for the six months ended June 30, 2013 and 2012, respectively.

Stock Based Compensation

We account for stock-based compensation in accordance with FASB ASC 718, *Compensation – Stock Compensation*. Under the provisions of FASB ASC 718, stock-based compensation cost is estimated at the grant date based on the award's fair value and is recognized as expense over the requisite service period. The company generally issues grants to its employees, consultants and board members. At the date of grant, the company determines the fair value of the stock option award and recognizes compensation expense over the requisite service period. The fair value of the stock option or warrant award is calculated using the Black Scholes option pricing model.

7

During the six months ended June 30, 2013 and 2012, warrants were granted to employees, directors and consultants of the Company. As a result of these grants, the Company recorded compensation expense of \$264,024 and \$21,441 for these periods, respectively.

The fair value of warrants was estimated on the date of grant using the Black-Scholes option-pricing model based on the following weighted average assumptions:

| | Six Months Ended June 30, | |
|---------------------|---------------------------|-------------------|
| | 2013 | 2012 |
| Expected volatility | 114.68% to 194.14% | 114.66 to 125.11% |
| Expected dividends | 0% | 0% |
| Expected term | 3 to 5 years | 3 years |
| Risk free rate | .25% | .25% to .33% |

The Black-Scholes option-pricing model was developed for use in estimating the fair value of traded options that have no vesting restrictions and are fully transferable. In addition, option-pricing models require the input of highly subjective assumptions, including the expected stock price volatility. Because the Company's employee warrants have characteristics significantly different from those of traded options and because changes in the subjective input assumptions can materially affect the fair value estimate, in management's opinion the existing models may not necessarily provide a reliable single measure of the fair value of its employee options.

Loss Per Share

Basic loss per share is computed by dividing the Company's net loss by the weighted average number of common shares outstanding during the period presented. Diluted loss per share is based on the treasury stock method and includes the effect from potential issuance of common stock such as shares issuable pursuant to the exercise of warrants and conversions of debentures. Potentially dilutive securities as of June 30, 2013, consisted of 31,198,000 common shares from convertible debentures and 14,828,876 common shares from outstanding warrants. Potentially dilutive securities as of June 30, 2012, consisted of 18,698,000 common shares from convertible debentures and 19,815,930 common shares from outstanding warrants. Diluted and basic weighted average shares are the same, as potentially dilutive shares are anti-dilutive.

Advertising / Public Relations Costs

Advertising/Public Relations costs are charged to operations when incurred. These expenses were \$12,341 and \$17,419 for the six months ended June 30, 2013 and 2012, respectively.

Concentrations of Credit Risk

Financial instruments that potentially subject the Company to significant concentrations of credit risk consist principally of cash and cash equivalents. The Company maintains cash balances at financial institutions which exceed the current Federal Deposit Insurance Corporation ("FDIC") limit of \$250,000 at times during the year.

Reclassifications

Certain reclassifications have been made to prior-year and prior period comparative financial statements to conform to the current year and period presentation. These reclassifications had no material effect on previously reported results of operations or financial position.

NOTE 3 - PROPERTY AND EQUIPMENT

Property and equipment at June 30, 2013 and December 31, 2012 consists of the following:

| | <u>June 30, 2013</u> (Unaudited) | <u>December 31, 2012</u> |
|--|-------------------------------------|--------------------------|
| Furniture and fixtures | \$ 3,017 | \$ 51,617 |
| Equipment | - | 112,879 |
| Leasehold improvements | - | 151,859 |
| | <u>3,017</u> | <u>316,355</u> |
| Less accumulated depreciation and amortization | <u>(3,017)</u> | <u>(303,152)</u> |
| | <u>\$ -</u> | <u>\$ 13,203</u> |

Depreciation and amortization was \$13,203 and \$34,566 for the six months ended June 30, 2013 and 2012 respectively. On March 31, 2013, the lease expired for the office and production space located in Scottsdale, Arizona. The Company closed this operation and subcontracted the production. Fully depreciated fixed assets of \$298,765 were written off as a result of the lease expiration.

NOTE 4 - DEFINITE-LIFE INTANGIBLE ASSETS

Definite-life intangible assets at June 30, 2013 and December 31, 2012 consist of the following:

| | <u>June 30, 2013</u> (Unaudited) | <u>December 31, 2012</u> |
|--------------------------------|-------------------------------------|--------------------------|
| Patent applications pending | \$ 14,501 | \$ 14,501 |
| Less: Accumulated amortization | <u>(14,501)</u> | <u>(8,267)</u> |
| | <u>\$ 0</u> | <u>\$ 6,234</u> |

The Company's definite-life intangible assets are amortized, upon being placed in service, over the estimated useful lives of the assets, with no residual value. Amortization expense for the six months ended June 30, 2013 and 2012 were \$6,234 and \$484, respectively. As of June 30, 2013, the Company's management has decided to take an impairment charge of \$6,234 representing the unamortized basis of the patents related to the creation and production of its product, ProAlgaZyme which is no longer producing revenue.

NOTE 5 – LOAN PAYABLE

Related Party

During 2012, Christopher Maggiore, a significant shareholder, advanced the Company \$15,000. As of December 31, 2012 this amount was still unpaid. During the six months ended June 30, 2013, Mr. Maggiore advanced the Company an additional \$535,000. As discussed in Note 6, this amount was reclassified as a loan payable to HEP Investments, LLC. As of June 30, 2013, there was no balance due to Mr. Maggiore.

Others

During 2012, the Venture Group loaned the Company \$57,000. Through June 30, 2013, an additional \$25,000 was loaned to the Company. This money was related to the overall financing of \$500,000 as further discussed in Note 6. As of June 30, 2013, there was still a balance due to the Venture Group of \$82,000.

As of December 31, 2012, HEP Investments had loaned the Company \$186,592, as part of its overall funding commitment of \$2,000,000. During the six months ended June 30, 2013, HEP Investments, LLC loaned the Company an additional \$1,521,000 (see Note 6 – Convertible Debt). Pursuant to the terms of our agreement with HEP Investments, \$1,500,000 of these loans were converted to Convertible Secured Promissory Notes, leaving a remaining balance of \$207,592 in loans payable – others as of June 30, 2013.

NOTE 6 – CONVERTIBLE DEBT

HEP Investments, LLC

On December 2, 2011, the Company and HEP Investments, LLC, a Michigan limited liability company (“Lender”), entered into the following documents, effective as of December 1, 2011: (i) a Loan Agreement under which the Lender has agreed to advance up to \$2,000,000 to the Company, subject to certain conditions, (ii) a Convertible Secured Promissory Note in the initial principal amount of \$600,000 (“Note”) and (iii) (a) a Security Agreement, under which the Company granted the Lender a security interest in all of its assets and (b) an IP security agreement under which the Company and its subsidiaries granted the Lender a security interest in all their respective intellectual properties, including patents, in each case order to secure their respective obligations to the Lender under the Note and related documents. In addition, the Company’s subsidiaries have guaranteed the Company’s obligations under the Note.

Amounts advanced under the Note are (i) secured by all the Company’s assets, (ii) convertible into the Company’s restricted common stock at the lesser of \$.12 per share or a 25% discount off of the ten day trailing quoted price of the common stock in the over the counter (OTC) market, (iii) bear interest at the rate of 11% per annum and (iv) must be repaid as follows: accrued interest must be paid on the first and second anniversary of the Note and unpaid principal not previously converted into common stock must be repaid on the second anniversary of the Note December 1, 2013. The Company issues a Note to the lender upon the advances matching an aggregate amount of \$250,000. The Company has also agreed to a specified use of proceeds. The Note may be prepaid upon sixty days written notice, provided that the Company shall be required to pay a prepayment premium equal to 5% of the amount repaid.

The Company has made certain agreements with the Lender which shall remain in effect as long as any amount is outstanding under the Loan. These agreements include an agreement not to make any change in the Company’s senior management, without the prior written consent of the Lender. Two representatives of the Lender will have the right to attend Board of Director meetings as non-voting observers.

As of December 5, 2011, the Lender had advanced the Company \$600,000, consisting of \$500,000 in cash and \$100,000 previously advanced by the Lender in connection with a transaction previously disclosed in a Current Report on Form 8-K dated September 12, 2011. The Lender has agreed to advance the remaining \$1,400,000 in \$250,000 increments (final increment of \$150,000) upon request of the Company’s CEO, subject to satisfaction of certain conditions. In addition, the Company has agreed to (i) issue the Lender warrants to purchase 1,666,667 shares of common stock at an exercise price of \$.12 per share (including a cashless exercise provision), expiring September 30, 2016 and (ii) enter into a Registration Rights Agreement with respect to all the shares of common stock issuable to the Lender in connection with the Loan transaction, in each case subject to completion of funding of the full \$2,000,000 called for by the Loan Agreement.

The Company recorded a debt discount of \$500,000 against this transaction. In addition, the Company recorded a derivative liability of \$552,988. This represents the future value of the stock to be issued under the terms of the convertible debt. We valued this stock utilizing the Black-Scholes method of valuation using the following assumptions: volatility 151.45%, annual rate of dividends 0% and a risk free interest rate of .27%. In addition, the Company has recognized other income of \$24,422 representing the change in fair value of this derivative liability. We marked this derivative liability to fair value at December 31, 2011 utilizing the Black-Scholes method of valuation using the following assumptions: volatility 151.49%, annual rate of dividends 0%, and a risk free rate of .25%.

During 2012, HEP Investments advanced the Company an additional \$500,000 on which the Company recorded a debt discount in the amount of \$500,000. This represents the future value of the stock to be issued under the terms of the convertible debt. We valued this stock utilizing the Black-Scholes method of valuation using the following assumptions: volatility of 140.93%-143.36%, annual rate of dividends 0% and a risk free interest rate of .25%. In connection with the \$500,000 in convertible notes, the Company recorded non-cash finance charges of \$16,575 during 2012.

On March 18, 2013, the Company was advised of a Participation Agreement between HEP Investments and Christopher Maggiore, a significant shareholder of the Company, whereby Mr. Maggiore has become a member of HEP Investments, LLC. Accordingly, loans made by Mr. Maggiore to the Company aggregating \$462,000 (\$15,000 at December 31, 2012 and \$447,000 during the period January 1, 2013 through March 5, 2013) have been reclassified as loans payable to HEP Investments pursuant to its previously disclosed agreement entered into on December 2, 2011 to invest up to \$2,000,000 in convertible notes. Upon this reclassification, HEP Investments, LLC reached a \$500,000 threshold and these advances were converted to convertible debt. The Company recorded a debt discount in the amount of \$377,088. This represents the future value of the stock to be issued under the terms of the convertible debt. We valued this stock utilizing the Black-Scholes method of valuation using the following assumptions: volatility of 160.96%, annual rate of dividends 0% and a risk free interest rate of .25.

On April 16, 2013, the Company and Lender, entered into the following documents, effective as of April 15, 2013: (i) First Amendment to Loan Agreement and (ii) an Amended and Restated Senior Secured Convertible Promissory Note. These agreements modified the term of agreements the Company entered into with HEP Investments on December 2, 2011 as discussed above. Pursuant to the terms of the modified agreements the Lender has agreed to advance up to a total of \$3,750,000 and extend the due date of each Note to two years from the date it was issued. The Company determined that the modification of the HEP Investments Loan Agreement was not a substantial modification in accordance with ASC 470-50, "Modifications and Extinguishments".

As of April 16, 2013, the Lender had advanced the Company \$2,707,780. Amounts advanced under the Note are (i) secured by all the Company's assets, (ii) convertible into the Company's restricted common stock at the lesser of \$.12 per share or a 25% discount off of the ten day trailing quoted price of the common stock in the over the counter (OTC) market and (iii) bear interest at the rate of 11% per annum.

Upon reaching a funding level of \$2,000,000 the Company was obligated pursuant to the terms of the Note to issue 1,666,667 of its common stock warrants, exercisable at \$.12 per share and expiring on September 30, 2016 as well as 600,000 shares of its common stock. The common stock was valued at \$192,000 based on a closing share price on April 15, 2013 of \$.32 per share. The Company valued the 1,666,667 common stock warrants at \$481,110 using the Black Scholes method of valuation using the following assumptions: exercise price of \$.12, a market value of \$.32, a remaining term of 3.46 years, volatility of 148.44%, annual rate of dividends of 0% and a risk free interest rate of 0.25%

Under the terms of the First Amendment to Loan Agreement and the Amended and Restated Senior Secured Convertible Promissory Note, the Lender has agreed to fund the remainder notes according to the following time lines:

The tranche between \$2 million and \$3 million must be funded within 20 days of the execution of the Note (April 15, 2013) in order for the Tranche to be convertible into the Company's restricted common stock at the lesser of \$.12 per share or a 25% discount off of the ten day trailing quoted price of the common stock in the over the counter (OTC) market. If any amount less than \$3 million is unfunded within the 20 day period, then the Tranche in excess of \$2 million is convertible into the Company's restricted common stock at the lesser of \$.22 per share or a 25% discount off of the ten day trailing quoted price of the common stock in the over the counter (OTC) market.

The tranche between \$3 million and \$3.75 million must be funded within 90 days of the execution of the Note and is convertible into the Company's restricted common stock at the lesser of \$.22 per share or a 25% discount off of the ten day trailing quoted price of the common stock in the over the counter (OTC) market.

Amounts advanced under the Note are (i) secured by all the Company's assets, (ii) bear interest at the rate of 11% per annum and (iii) must be repaid as follows: accrued interest must be paid on the first and second anniversary of the \$250,000 tranche and unpaid principal not previously converted into common stock must be repaid on the second anniversary of the Tranche.

The agreements made with HEP Investments on December 2, 2011 regarding the Company's obligation to not make any changes to senior management without the prior written consent of the Lender and the Lender's right to have two representatives attend Board of Director meetings as non-voting observers, for as long as any outstanding debt remains in effect.

During the three months ended June 30, 2013, HEP Investments advanced the Company an additional \$971,000. HEP Investments has reached a \$1,000,000 threshold (including monies advanced during the three months ended March 31, 2013) and these advances have been converted into convertible debt. The Company recorded a debt discount in the amount of \$1,000,000. This represents the future value of the stock to be issued under the terms of the convertible debt. We valued this stock utilizing the Black-Scholes method of valuation using the following assumptions: expected volatilities of 151.37%-153.70%, annual rate of dividends 0% and a risk free interest rates of 0.20-0.24%.

As of June 30, 2013, there was a remaining balance of \$207,592 in loans payable –others (Note 5).

The Venture Group, LLC

On January 27, 2012, the Company and The Venture Group, LLC, a Maryland limited liability company ("Venture Group"), entered into the following agreements, effective as of January 26, 2012: (i) a Subscription Agreement under which the Lender has agreed to advance \$500,000 to the Company, as follows: \$332,000 on January 26, 2012, which advance has been made, and \$168,000 by February 3, 2012, (ii) a Subordinated Convertible Promissory Note in the principal amount of \$500,000 ("Note"); (iii) (a) a Security Agreement, under which the Company granted the Lender a subordinated security interest in all of its assets and (b) an IP security agreement under which the Company granted the Lender a subordinated security interest in all its intellectual properties, including patents, to secure its obligations to the Lender under the Note and related documents; and (iv) a Termination and Mutual Release Agreement under which the Company and Venture Group terminated their prior agreements and released each other from any liability, including liabilities related to the financing agreements they previously executed (See Form 8-K Current Report dated December 2, 2011). In addition, the Company and Oxford Holdings LLC entered into a Termination and Release Agreement under which the Company and Oxford Holdings, LLC terminated their prior agreement and Oxford Holdings released the Company from any liability, including liabilities related to the agreement they previously executed. The Company also acknowledged an intercreditor agreement between Venture Group and HEP Investments, LLC, the Company senior secured lender. As of June 30, 2013, Venture Group has advanced an aggregate of \$414,000 to the Company. \$332,000 has been classified as a convertible debenture payable and the remainder \$82,000 has been classified as Loan Payable – Other (Note 5).

Subsequent to the balance sheet date The Venture Group, LLC completed funding of its \$500,000 obligation to the Company (see Note 12 – Subsequent Events).

Convertible debt consists of the following:

| | <u>June 30, 2013</u> (Unaudited) | <u>December 31, 2012</u> |
|---|-------------------------------------|--------------------------|
| 1% Convertible notes payable, net of unamortized discount of \$23,562 and \$45,300 respectively, due at various dates ranging from January 2014 to September 2014 | \$ 462,038 | \$ 440,300 |
| 11% Convertible note payable, net of unamortized discount of \$1,633,665 and \$695,935, respectively, due at various dates ranging from December 2013 to May 2015 | <u>1,198,335</u> | <u>636,066</u> |
| | 1,660,373 | 1,076,366 |
| Less: Current portion | <u>1,260,989</u> | <u>482,458</u> |
| Long term portion | <u>\$ 399,384</u> | <u>\$ 593,908</u> |

Amortization of the debt discount on the remaining notes was \$461,095 and \$286,341 for the six months ended June 30, 2013 and 2012, respectively.

NOTE 7 - DERIVATIVE LIABILITY

As part of the funding agreement signed December 1, 2011 with HEP Investments, LLC, the Company recorded a derivative liability of \$552,988. This represents the future value of the stock to be issued under the terms of the convertible debt. This derivative liability was valued utilizing the Black-Scholes method of valuation using the following assumptions: closing stock price of \$.17, expected volatility of 151.45% over the two year contractual life of the note, an annual rate of dividends 0% and a risk free interest rate of .27%. In addition, the Company has recognized other income of \$24,422 representing the change in fair value of this derivative liability. We marked this derivative liability to fair value at December 31, 2011 utilizing the Black-Scholes method of valuation using the following assumptions: closing stock price of \$.25, a volatility of 151.49% over the remaining 1.92 year contractual life of the note, an annual rate of dividends of 0%, and a risk free rate of .25%.

On April 4, 2012, as part of the HEP Investments agreement, as a result of reaching certain funding thresholds, the Company was required to record an additional derivative liability of \$496,375 utilizing the Black-Scholes method of valuation using the following assumptions: closing stock price of \$.29, an expected volatility of 143.36% over the remaining 1.66 year contractual life of the note, an annual rate of dividends of 0%, and a risk free rate of .25%.

On May 8, 2012, as part of the HEP Investments agreement, as a result of reaching certain funding thresholds, the Company was required to record an additional derivative liability of \$507,916 utilizing the Black-Scholes method of valuation using the following assumptions: closing stock price of \$.29, an expected volatility of 140.93% over the remaining 1.57 year contractual life of the note, an annual rate of dividends of 0%, and a risk free rate of .25%.

On December 31, 2012, the Company valued the derivative liability at \$1,026,128 utilizing the Black-Scholes method of valuation using the following assumptions: closing stock price of \$.19, an expected volatility of 151.75% over the remaining 0.92 year contractual life of the note, an annual rate of dividends of 0%, and a risk free rate of .26%. The fair value of the derivative decreased by \$506,729 which has been recorded in the statement of operations for the year ended December 31, 2012.

On March 18, 2013, as part of the HEP Investments agreement, as a result of reaching certain funding thresholds, the Company was required to record an additional derivative liability of \$377,088 utilizing the Black-Scholes method of valuation using the following assumptions: closing stock price of \$.22, an expected volatility of 160.96% over the remaining 0.71 year contractual life of the note, an annual rate of dividends of 0%, and a risk free rate of .25%.

On April 10, 2013, as part of the HEP Investments agreement, as a result of reaching certain funding thresholds, the Company was required to record an additional derivative liability of \$616,040 utilizing the Black-Scholes method of valuation using the following assumptions: closing stock price of \$.35, an expected volatility of 151.37% over the remaining 2.00 year contractual life of the note, an annual rate of dividends of 0%, and a risk free rate of .24%.

On April 16, 2013, as part of the HEP Investments agreement, as a result of reaching certain funding thresholds, the Company was required to record an additional derivative liability of \$518,756 utilizing the Black-Scholes method of valuation using the following assumptions: closing stock price of \$.30, an expected volatility of 151.72% over the remaining 2.00 year contractual life of the note, an annual rate of dividends of 0%, and a risk free rate of .24%.

On April 29, 2013, as part of the HEP Investments agreement, as a result of reaching certain funding thresholds, the Company was required to record an additional derivative liability of \$856,410 utilizing the Black-Scholes method of valuation using the following assumptions: closing stock price of \$.47, an expected volatility of 153.70% over the remaining 2.00 year contractual life of the note, an annual rate of dividends of 0%, and a risk free rate of .20%.

On May 7, 2013, as part of the HEP Investments agreement, as a result of reaching certain funding thresholds, the Company was required to record an additional derivative liability of \$916,028 utilizing the Black-Scholes method of valuation using the following assumptions: closing stock price of \$.50 an expected volatility of 153.46% over the remaining 2.00 year contractual life of the note, an annual rate of dividends of 0%, and a risk free rate of .22%.

On June 30, 2013, the Company valued the derivative liability at \$5,692,826 utilizing the Black-Scholes method of valuation using the following assumptions: closing stock price of \$.35, an expected volatility of 147.58% over the remaining contractual lives of the note ranging from 0.42-1.85 years, an annual rate of dividends of 0%, and a risk free rate of .25%. The fair value of the derivative increased by \$ 1,382,376 which has been recorded in the statement of operations for the six months ended June 30, 2013.

NOTE 8 – OBLIGATION TO ISSUE COMMON STOCK

As of December 31, 2012, the Company was obligated to issue an aggregate of 1,740,698 shares of common stock valued at \$337,478 to certain investors and Great Northern Reserve Partners, LLC, a former consultant (Andrew Dahl, CEO of the Company, was principal partner of Great Northern and Reserve Partners).

As of June 30, 2013, the Company has reclassified its obligation to issue an aggregate of 1,385,320 shares of common stock valued at \$277,064 to Great Northern Reserve Partners, LLC (“GNRP”) to accrued liabilities. This reclassification is the result of a Board Resolution passed on July 19, 2013 whereby the Company agreed to repay its debt to GNRP in cash rather than in common stock (see Note 12 – Subsequent Events).

During the quarter ended June 30, 2013, the Company issued 600,000 shares of common stock valued at \$72,000 to certain investors according to the terms of a Convertible Note (see Note 6 – Convertible Debt).

The balance due to certain investors is 2,278 shares of common stock valued at \$273 as of June 30, 2013.

NOTE 9 – SETTLEMENT AGREEMENT

On June 12, 2013, the Company entered into a Settlement Agreement and Mutual Release of all Claims (the “Settlement Agreement”) with Ceptazyme, LLC (“Ceptazyme”) and Zus Health, LLC (“Zus Health”) resolving claims the parties brought against one another in connection with a license agreement between the Company and Zus Health dated September 2, 2010 (the “License Agreement”). Under the terms of the Settlement Agreement, the parties agreed to terminate the License Agreement and that no party would have any further obligations thereunder. No monetary consideration was exchanged in connection with the Settlement Agreement.

The dispute under the Settlement Agreement arose when Zus Health attempted to assign the License Agreement to Ceptazyme. On January 9, 2012, the Company notified Ceptazyme (i) that there was no agreement between the Company and Ceptazyme, as the Company had not approved any assignment of the License Agreement by Zus Health to Ceptazyme and (ii) that, even if there had been a valid assignment to Ceptazyme, Ceptazyme had committed multiple material breaches of the agreement. The Company believes that Ceptazyme (i) failed to market the Company’s product in a manner compliant with state and federal regulations, and (ii) allowed its distributors to make claims and representations that were not in compliance with applicable regulations, among many other breaches. As a result, the Company filed a lawsuit in Michigan against Zus Health and Ceptazyme on January 16, 2012, alleging breach of contract. Ceptazyme responded by filing suit in Utah against the Registrant on January 24, 2012, also alleging, breach of contract.

As a result of this settlement, the deferred revenue of \$235,000 and customer deposits of \$27,837 were recognized as other income.

NOTE 10 - STOCKHOLDERS’ DEFICIT

Board of Directors fees

As compensation for joining the board of directors in January of 2012, the Company granted warrants to purchase 200,000 shares of common stock to Philip M. Rice (CFO and a Director) in January, 2012, at an exercise price of \$.12 per share. The warrants have a term of three years and vest as follows: 50,000 were vested on the grant date with the remainder vesting throughout 2012 on a quarterly basis. The warrants vested during the quarter ended March 31, 2012, and each subsequent quarter, were valued at \$10,721 using the Black Scholes pricing model with the following assumptions: volatility of 125.11%; annual rate of dividends 0%; and a risk free rate of 0.33%.

As compensation for joining the board of directors in June of 2012, the Company granted warrants to purchase 50,000 shares of common stock to Brian Young. The warrants were granted with an exercise price of \$.12 per share, have a term of three years and vested as follows: 12,500 vested on the grant date, 12,500 vested on September 30, 2012, 12,500 vested on December 31, 2012 and 12,500 vested on March 31, 2013. The warrants were valued at \$8,921 using the Black Scholes pricing model relying on the following assumptions: volatility 114.66%; annual rate of dividends 0%; discount rate 0.25%. In addition, Mr. Young will receive \$10,000 for each annual term served, paid quarterly.

As compensation for serving as a member of the board of directors, the Company granted warrants to purchase 50,000 shares of common stock to John Gorman (EVP and a Director) in November, 2012, at an exercise price of \$.12 per share. The warrants have a term of three years and vested or will vest as follows: 12,500 vested on the grant date, 12,500 vested on March 31, 2013 and the remaining 25,000 shall vest on quarterly (12,500 per quarter). The warrants were valued at \$4,848 using the Black Scholes pricing model relying on the following assumptions: volatility 128.51%; annual rate of dividends 0%; discount rate 0.27%. In addition, Mr. Gorman will receive \$10,000 for each annual term served, paid quarterly.

During 2012, the Company issued 5,270,000 shares of common stock and 492,000 warrants to purchase shares of common stock for \$650,000. Also, an investor received 11,797 shares as part of a cashless exercise of 233,333 common stock warrants that had an exercise price of \$.15.

As compensation for serving as a member of the board of directors, the Company granted warrants to purchase 50,000 shares of common stock to Philip M. Rice (CFO and a Director) in January, 2013, at an exercise price of \$.12 per share. The warrants have a term of three years and vested or will vest as follows: 12,500 vested on the grant date and the remaining 37,500 shall vest quarterly (12,500 per quarter). The warrants were valued at \$10,381 using the Black Scholes pricing model relying on the following assumptions: volatility 131.97%; annual rate of dividends 0%; discount rate 0.27%. In addition, Mr. Rice will receive \$10,000 for each annual term served, paid quarterly.

As compensation for serving as a member of the board of directors, the Company granted warrants to purchase 50,000 shares of common stock to Thomas K. Cox in June, 2013, at an exercise price of \$.40 per share. The warrants have a term of three years and vested or will vest as follows: 12,500 vested on the grant date and the remaining 37,500 shall vest quarterly (12,500 per quarter). The warrants were valued at \$15,873 using the Black Scholes pricing model relying on the following assumptions: volatility 145.67%; annual rate of dividends 0%; discount rate 0.25%. In addition, Mr. Cox will receive \$10,000 for each annual term served, paid quarterly.

The company recorded Directors Fees of \$13,385 during the six months ended June 30, 2013, representing the value of the vested warrants described above.

Stock Issuances

During the three months ended March 31, 2013, an investor received 21,111 shares as part of a cashless exercise of 35,000 common stock warrants that had an exercise price of \$.10.

During the three months ended June 30, 2013, investors received 1,191,181 shares as part of cashless exercises of 1,400,000 common stock warrants that had exercise prices at \$.15. In addition the Company received proceeds of \$85,000 from the exercise of 682,000 common stock warrants.

On April 15, 2013, upon completion of funding on a \$2,000,000, 11% convertible debenture, the Company issued 600,000 shares of its common stock valued at \$192,000 and 1,666,667 common stock warrants valued at \$481,110 using the Black Scholes method of valuation (see Note 6 – Convertible Debt).

On April 30, 2013, the Company Board of Directors awarded its Chief Financial Officer 557,000, 5 year common stock warrants, exercisable at \$.25 per share. These warrants were valued at \$250,640 using the Black Scholes valuation method of valuation using the following assumptions: closing stock price of \$.46 an expected volatility of 194.14% a five year term, an annual rate of dividends of 0%, and a risk free rate of .25%.

A summary of the status of the Company's warrants is presented below.

| | June 30, 2013 | | December 31, 2012 | |
|--------------------------------|--------------------|---------------------------------|--------------------|---------------------------------|
| | Number of Warrants | Weighted Average Exercise Price | Number of Warrants | Weighted Average Exercise Price |
| Outstanding, beginning of year | 16,365,209 | \$ 0.17 | 20,413,430 | \$ 0.19 |
| Issued | 2,248,667 | 0.15 | 1,425,112 | 0.12 |
| Exercised | (2,285,000) | 0.16 | (583,333) | 0.15 |
| Expired | (1,500,000) | 0.32 | (4,890,000) | 0.23 |
| Outstanding, end of period | <u>14,828,876</u> | <u>\$ 0.16</u> | <u>16,365,209</u> | <u>\$ 0.17</u> |

Warrants outstanding and exercisable by price range as of June 30, 2013 were as follows:

| Outstanding Warrants | | | Exercisable Warrants | | |
|----------------------|-------------------|--|----------------------|-------------------|---------------------------------|
| Range of | Number | Average Weighted Remaining Contractual Life in Years | Exercise Price | Number | Weighted Average Exercise Price |
| \$ 0.12 | 2,532,279 | 1.74 | \$ 0.12 | 890,612 | \$.12 |
| 0.125 | 7,114,597 | 1.34 | 0.125 | 7,114,597 | 0.125 |
| 0.15 | 1,350,000 | .69 | 0.15 | 1,350,000 | 0.15 |
| 0.225 | 200,000 | .36 | 0.225 | 200,000 | 0.225 |
| 0.25 | 3,632,000 | 2.27 | 0.25 | 3,682,000 | 0.25 |
| | <u>14,828,876</u> | <u>1.37</u> | | <u>13,240,360</u> | <u>\$ 0.17</u> |

NOTE 11- COMMITMENTS AND CONTINGENCIES

Employment Agreement

The Company's Chief Executive Officer, Andrew Dahl, is serving under the terms of an employment agreement dated, December 16, 2011. Under the agreement Mr. Dahl will serve as CEO for one year, subject to automatic renewal for successive one year terms, unless either party terminates the Agreement on sixty days' notice prior to the expiration of the term of the agreement. Mr. Dahl will be compensated as follows: he will receive an annual base salary of \$240,000. In addition, Mr. Dahl is entitled to monthly bonus compensation equal to 2% of the Company's revenue, but only to the extent that such bonus amount exceeds his base salary for the month in question. In addition, Mr. Dahl will be entitled to warrants having an exercise price of \$.25 per share, upon the attainment of specified milestones as follows: 1) Warrants for 500,000 shares upon identification of bio-active agents in the Company's product and filing of a patent with respect thereto, 2) Warrants for 500,000 shares upon entering into a business contract under which the Company receives at least \$500,000 in cash payments, 3) Warrants for 1,000,000 shares upon the Company entering into a co-development agreement with a research company to develop medicinal or pharmaceutical applications (where the partner provides at least \$2 million in cash or in-kind outlays), 4) Warrants for 1,000,000 shares upon the Company entering into a co-development agreement for nutraceutical or dietary supplement applications (where the partner provides at least \$2 million in cash or in-kind outlays), 5) Warrants for 1,000,000 shares upon the Company entering into a pharmaceutical development agreement. As of June 30, 2013, none of the milestones referred to had been achieved.

Miscellaneous Receivable

On May 1, 2013, the Company, through its legal counsel, sent a notice to the landlord at 7740 E. Evans, Scottsdale, AZ that it expected a timely return of the \$118,466 security deposit. On June 14, 2013, the landlord filed a Complaint in the State Court of Arizona that the Company owed the landlord in excess of \$210,000 in damages related to the property at 7740 E. Evans, Scottsdale, AZ. On July 24, 2013, the Company filed an Answer and Counter Claim disputing the claim and asking the court for relief in the amount of \$118,466. The Company believes it will recover all of the security deposit. The Company believes that this case has no merit and the outcome will have no material effect on its financial position or results of operations.

NOTE 12 - SUBSEQUENT EVENTS

Board of Director Member

On July 19, 2013, the Company appointed John Payne as a member of the board of directors. As compensation for serving as a member of the board of directors, the Company granted warrants to purchase 50,000 shares of common stock to Mr. Payne in July, 2013, at an exercise price of \$.38 per share. The warrants have a term of three years and vested or will vest as follows: 12,500 vested on the grant date and the remaining 37,500 shall vest quarterly (12,500 per quarter). In addition, Mr. Payne will receive \$10,000 for each annual term served, paid quarterly.

GNRP

On July 19, 2013, the board of directors passed a Resolution whereby the Company agreed to repay its debt of \$277,064 to Great Northern Reserve Partners (GNRP) in cash rather than in common stock (see Note 8 – Obligation to Issue Common Stock).

HEP Investments

From July 1, 2013 to August 8, 2013, the Lender has advanced the Company an additional \$342,408 for a total amount advanced of \$3,050,000. Amounts advanced under the Note are (i) secured by all the Company's assets, (ii) convertible into the Company's restricted common stock at the lesser of \$.12 per share or a 25% discount off of the ten day trailing quoted price of the common stock in the over the counter (OTC) market for the first \$2,707,592 and the remainder is convertible into the Company's restricted common stock at the lesser of \$.22 per share or a 25% discount off of the ten day trailing quoted price of the common stock in the OTC market, and (iii) bear interest at the rate of 11% per annum (see Note 6 – Convertible Debt).

The Venture Group, LLC

As of July 22, 2013, The Venture Group, LLC completed the full \$500,000 funding, with the last \$86,000 received on July 22, 2013. Upon this final funding, the Company will issue 200,000, 2 year common stock warrants exercisable at \$.15 per share to Oxford Holdings, LLC ("Oxford") pursuant to a Termination and Mutual Release Agreement reached between the Company and Oxford.

Also, as a result of the completed funding the Company must issue an additional 280,000, 3 year common stock warrants exercisable at \$.12 per share to The Venture Group, LLC pursuant the terms of the Subscription Agreement and Subordinated Convertible Promissory Note dated January 26, 2012 (see Note 6 – Convertible Debt).

Stock Issuances

As of August 6, 2013, the Company has received an aggregate of \$325,000 from the sale of units of 1,477,273 shares of common stock and 147,727 common stock warrants at \$.22 per unit. The warrants will be exercisable at \$.22 per share and will expire in three (3) years from the date of issuance.

In addition, the Company received \$6,000 from the exercise of 50,000 common stock warrants at \$.12 per share.

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations

SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS

Some of the statements contained in this report are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements involve known and unknown risks, uncertainties and other factors which may cause our or our industry's actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Forward-looking statements include, but are not limited to statements regarding:

- our ability to raise the funds we need to continue our operations;
- our goal to increase our revenues and become profitable;
- regulation of our product;
- market acceptance of our product and derivatives thereof;
- the results of current and future testing of our product;
- the anticipated performance and benefits of our product;
- the ability to generate licensing fees; and
- our financial condition or results of operations.

In some cases, you can identify forward-looking statements by terms such as "may, will, should, could, would, expects, plans, anticipates, believes, estimates, projects, predicts, potential" and similar expressions intended to identify forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors that may cause our actual results, levels of activity, performance, or achievements to be materially different from any future results, levels of activity, performance, or achievements expressed or implied by such forward-looking statements. Given these uncertainties, you should not place undue reliance on these forward-looking statements. Also, these forward-looking statements represent our estimates and assumptions only as of the date of this report. Except as otherwise required by law, we expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward-looking statement contained in this report to reflect any change in our expectations or any change in events, conditions or circumstances on which any of our forward-looking statements are based. We qualify all of our forward-looking statements by these cautionary statements.

Critical Accounting Policies

The accompanying discussion and analysis of our financial condition and results of operations are based upon our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America ("US GAAP"). The preparation of these financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues, and expenses, and related disclosure of contingent assets and liabilities. These estimates form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We base our estimates and judgments on historical experience and all available information. However, future events are subject to change, and the best estimates and judgments routinely require adjustment. US GAAP requires us to make estimates and judgments in several areas, including those related to recording various accruals, income taxes, the useful lives of long-lived assets, such as property and equipment and intangible assets, and potential losses from contingencies and litigation. We believe the policies discussed below are the most critical to our financial statements because they are affected significantly by management's judgments, assumptions and estimates.

Results of Operations for the Three Months ended June 30, 2013 and 2012.

Net Sales.

We had no sales during the three months ended June 30, 2013 and 2012. We implemented a new business model starting in 2012, and expect to derive future income from licensing and sale of the natural bioactive ingredients derived from algae cultures to much larger, better-financed animal, food, dietary supplement and medical food manufacturers. The anticipated income streams are to be generated from a) royalties and advances for licensed natural bioactive ingredients, and b) bulk sales of such ingredients. These bulk ingredients will be made by contracted ingredient manufacturers and then sold by us to food, dietary supplement and medical food processors and/or name-brand marketers. We do not believe it likely that we will have significant sales in 2013.

Cost of Sales.

We had no cost of sales during the three months ended June 30, 2013 and 2012.

Research and Development Expenses.

For the three months ended June 30, 2013, we incurred \$310,917 in research and development expenses, as compared to \$182,417 for the comparable period in 2012. These expenses are mainly comprised of costs associated with external research. Our research and development costs will grow as we work to complete the research in the development of natural bioactive compounds for use as dietary supplements and food ingredients, as well as biologics for medicinal and pharmaceutical applications in humans and animals. The Company's scientific efforts are focused on the metabolic aspects of oxidation and inflammation, with a parallel program to validate and license products for healthy cholesterol balance.

Selling and Marketing Expenses.

We had no selling and marketing expenses during the three months ended June 30, 2013 and 2012.

General and Administrative Expenses.

General and administrative expenses were \$472,003 for the three months ended June 30, 2013, as compared to \$162,453 for the comparable prior period. The increase in general and administrative expense during 2013 is due primarily to a warrant granted to the Chief Financial Officer for 557,000 shares of common stock whereby the Company recorded a compensation expense (non-cash) of \$251,000.

Professional and Consulting Expenses.

Professional and consulting expenses were \$99,480 for the three months ended June 30, 2013, as compared to \$136,914 for the comparable prior period. The decrease in professional and consulting expense during 2013 is due primarily to a reduction in of in legal fees offset by an increase in the use of outside business consultants.

Results of Operations for the six months ended June 30, 2013 and 2012.

Net Sales.

We had no sales during the six months ended June 30, 2013 and 2012. We implemented a new business model starting in 2012, and expect to derive future income the from the licensing and sale of natural bioactive ingredients derived from algae cultures to much larger, better-financed animal, food, dietary supplement and medical food manufacturers. The anticipated income streams are to be generated from a) royalties and advances for licensed natural bioactive ingredients, and b) bulk sales of such ingredients. These bulk ingredients will be made by contracted ingredient manufacturers and then sold by us to food, dietary supplement and medical food processors and/or name-brand marketers. We do not believe it likely that we will have significant sales in 2013.

Cost of Sales.

We had no cost of sales during the six months ended June 30, 2013 and 2012.

Research and Development Expenses.

For the six months ended June 30, 2013, we incurred \$440,365 in research and development expenses, as compared to \$305,468 for the comparable period in 2012. These expenses are mainly comprised of costs associated with external research. Our research and development costs will grow as we work to complete the research in the development of natural bioactive compounds for use as dietary supplements and food ingredients, as well as biologics for medicinal and pharmaceutical applications in humans and animals. The Company's scientific efforts are focused on the metabolic aspects of oxidation and inflammation, with a parallel program to validate and license products for healthy cholesterol balance.

Selling and Marketing Expenses.

We had no selling and marketing expenses during the six months ended June 30, 2013 and 2012.

General and Administrative Expenses.

General and administrative expenses were \$736,416 for the six months ended June 30, 2013, as compared to \$315,938 for the comparable prior period. The increase in general and administrative expense during 2013 is due primarily to a warrant granted to the Chief Financial Officer for 557,000 shares of common stock whereby the Company recorded a compensation expense (non-cash) of \$251,000.

Professional and Consulting Expenses.

Professional and consulting expenses were \$240,956 for the six months ended June 30, 2013, as compared to \$367,597 for the comparable prior period. The decrease in professional and consulting expense during 2013 is due primarily to a reduction in legal fees and offset by an increase in the use of outside business consultants.

Liquidity and Capital Resources

The unaudited condensed consolidated financial statements contained in this Quarterly Report have been prepared on a “going concern” basis, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business. We have a near term need for additional capital. For the reasons discussed herein, there is a significant risk that we will be unable to continue as a going concern, in which case, you would suffer a total loss of your investment in our company.

As of August 8, 2013, we had a cash balance of approximately \$700,000. We have incurred significant net losses since inception, including a net loss of \$5,676,436 for the six months ended June 30, 2013. We have, since inception, consistently incurred negative cash flow from operations. During the six months ended June 30, 2013, we incurred negative cash flows from operations of \$1,408,181. As of June 30, 2013, we had a working capital deficiency of \$8,211,954 and a stockholders’ deficiency of \$8,610,493. Although we recently raised a limited amount of capital, we have a near term need for additional capital.

During the six months ended June 30, 2013, our operating activities used \$1,408,181 in cash, an increase of \$460,180 from the comparable prior period. The approximate \$460,200 increase in cash used by operating activities was primarily attributable to the following (all of which are approximated): a \$3,869,000 increase in net loss, offset by \$3,900,000 in non-cash expenses and a \$51,000 change (increase) in prepaid expenses, a \$198,000 change (decrease) in accounts payable, a \$263,000 change (decrease) in deferred revenue and customer deposits, offset by a \$16,000 change (increase) in accrued liabilities.

Our financing activities generated \$1,615,600, a \$794,300 increase from the comparable prior period. The increase in cash provided by financing activities was due primarily to a \$743,000 increase in proceeds from the issuance of convertible debentures, a \$35,000 increase in proceeds from sales of common stock and exercise of warrants, a decrease of \$35,000 in payment of deferred finance costs offset by a decrease of \$26,000 decrease in loans payable – other.

Although we raised a limited amount of capital during 2012 and the six months of 2013, we continue to experience a shortage of capital, which is materially and adversely affecting our ability to run our business. As noted above, we have been largely dependent upon external sources for funding. We have in the past had great difficulty in raising capital from external sources. We will still be reliant upon external financing for the continuation of our research programs.

We estimate that we will require approximately \$2,500,000 in cash over the next 12 months in order to fund our normal operations and research and development activities. Based on this cash requirement, we have a near term need for substantial additional funding. Historically, we have had great difficulty raising funds from external sources; however, we recently were able to raise capital from outside sources. If we are unable to raise the required funding, we will have to curtail our research and development and other activities, in which case, there could be a material adverse effect on our business.

Significant elements of income or loss not arising from our continuing operations

We do not expect to experience any significant elements of income or loss other than those arising from our continuing operation. For the six months ended June 30, 2013, we recognized \$1,382,376 in expense for financial statement purposes, due to the change in fair value of derivative liabilities as of June 30, 2013. We may incur income or expense in future periods arising out of changes in the fair value of derivative liabilities.

Seasonality

Based on our business model implemented at the beginning of 2013, anticipated income streams are to be generated from a) royalties and advances for licensed natural bioactive ingredients, and b) bulk sales of such ingredients. We do not anticipate that these will be affected by seasonality.

Staffing

We have conducted all of our activities since inception with a minimum level of qualified staff. We currently do not expect a significant increase in staff.

Off-Balance Sheet arrangements

We have no off-balance sheet arrangements that would create contingent or other forms of liability.

Item 4 Controls and Procedures

Management's Report on Disclosure Controls and Procedures.

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our Securities Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to our management, including our Chief Financial Officer, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, we recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving the desired control objectives, as ours are designed to do, and we necessarily were required to apply our judgment in evaluating the cost-benefit relationship of possible changes or additions to our controls and procedures.

As of June 30, 2013, we carried out an evaluation, under the supervision and with the participation of our management, including our principal executive/principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934. Based upon that evaluation, our principal executive/principal financial officer concluded that our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, are effective in enabling us to record, process, summarize and report information required to be included in our periodic SEC filings within the required time period.

Changes in Internal control Over Financial Reporting.

There have been no changes in our internal control over financial reporting that occurred during the period covered by this report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

During the six months ended June 30, 2013, the Company issued Convertible debentures in the principal amount of \$1,500,000 (convertible into common stock at \$.12 per share), for gross proceeds of \$1,500,000.

During the six months ended June 30, 2013, the Company issued 682,000 shares common stock for gross proceeds of \$85,000.

We believe that the foregoing transactions were exempt from the registration requirements under Rule 506 of Regulation D promulgated under the Securities Act of 1933, as amended (“the Act”) or Section 4(2) under the Act, based on the following facts: there was no general solicitation, there was a limited number of investors, each of whom was an “accredited investor” (within the meaning of Regulation D under the “1933 Act”, as amended) and was (either alone or with his/her purchaser representative) sophisticated about business and financial matters, each such investor had the opportunity to ask questions of our management and to review our filings with the Securities and Exchange Commission, and all shares issued were subject to restrictions on transfer, so as to take reasonable steps to assure that the purchasers were not underwriters within the meaning of Section 2(11) under the 1933 Act.

Item 5. Other Information

From July 1, 2013 through August 8, 2013: 1) we received \$86,000 from the Venture Group which completed their total funding commitment of \$500,000, 2) received \$6,000 from the sale of common stock through the exercise of a warrant, 3) received \$325,000 from the sale of common stock by subscription agreements and 4) received \$342,408 from HEP Investments, for a total cumulative funding of \$3,050,000 relating to their additional funding relating of the First Amendment to Loan Agreement under which the Lender has agreed to advance up to a total of \$3,750,000.

Item 6. Exhibits

| Exhibit Number | Description |
|----------------|---|
| 31.1* | Certification of the Principal Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended |
| 31.2* | Certification of the Principal Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a) of the Securities Exchange Act of 1934, as amended |
| 32.1* | Certification of the Principal Executive Officer pursuant to U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
| 32.2* | Certification of the Principal Financial Officer pursuant to U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |

*Furnished herewith (all other exhibits are deemed filed)

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

HEALTH ENHANCEMENT PRODUCTS, INC.

Date: August 12, 2013

By: /s/Andrew Dahl
Andrew Dahl
Chief Executive Officer

Exhibit 31.1

**Certification Pursuant to pursuant to Rule 13a-14(a) or Rule 15d-14(a)
of the Securities Exchange Act of 1934, as amended**

I, Andrew Dahl, certify that:

1. I have reviewed this quarterly report on Form 10-Q of the Company;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rule 13a-15(f) and 15d-15(f)) for the registrant and have:
 - a) designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
 - b) designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c) evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
 - d) disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the period covered by this report that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent function).
 - a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 12, 2013

/s/Andrew Dahl

Andrew Dahl,
Chief Executive Officer

**Certification Pursuant to pursuant to Rule 13a-14(a) or Rule 15d-14(a)
of the Securities Exchange Act of 1934, as amended**

I, Philip M. Rice II, certify that:

1. I have reviewed this Quarterly report on Form 10-Q of Health Enhancement Products, Inc. (the "Company");
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The Registrants other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f) for the registrant and have:
 - a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure the material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly through the period in which this report is being prepared;
 - b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
 - c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluations, and
 - d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of registrant's board of directors (or persons performing the equivalent function):
 - a) all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
 - b) any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 12, 2013

/s/Philip M. Rice II
Philip M. Rice II
Chief Financial Officer

**CERTIFICATION PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
(Subsections (a) and (b) of Section 1350,
Chapter 63 of Title 18, United States Code)**

In connection with the Quarterly Report on Form 10-Q for the period ending June 30, 2013 of Health Enhancement Products, Inc., a Nevada corporation (the "Company"), as filed with the Securities and Exchange Commission (the "Report"), I, Andrew Dahl, Chief Executive Officer of the Company, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350), that to the best of my knowledge and belief:

- (1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and
- (2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: August 12, 2013

/s/Andrew Dahl
Andrew Dahl
Chief Executive Officer

A SIGNED ORIGINAL OF THIS WRITTEN STATEMENT REQUIRED BY SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 HAS BEEN PROVIDED TO HEALTH ENHANCEMENT PRODUCTS, INC. AND WILL BE RETAINED BY HEALTH ENHANCEMENT PRODUCTS, INC. AND FURNISHED TO THE SECURITIES AND EXCHANGE COMMISSION OR ITS STAFF UPON REQUEST

**CERTIFICATION PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
(Subsections (a) and (b) of Section 1350,
Chapter 63 of Title 18, United States Code)**

In connection with the Annual Report of Health Enhancement Products, Inc., a Nevada corporation (the "Company"), on Form 10-Q for the period June 30, 2013 as filed with the Securities and Exchange Commission (the "Report"), I, Philip M. Rice II, Chief Financial Officer of the Company, certify, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, 18 U.S.C. Section 1350), that to the best of my knowledge and belief:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78o(d)); and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

Date: August 12, 2013

/s/ Philip M. Rice II

Philip M. Rice II
Chief Financial Officer

A SIGNED ORIGINAL OF THIS WRITTEN STATEMENT REQUIRED BY SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 HAS BEEN PROVIDED TO HEALTH ENHANCEMENT PRODUCTS, INC. AND WILL BE RETAINED BY HEALTH ENHANCEMENT PRODUCTS, INC. AND FURNISHED TO THE SECURITIES AND EXCHANGE COMMISSION OR ITS STAFF UPON REQUEST.